WARFARIN SODIUM- warfarin sodium tablet
TVA Pharmaceuticals

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use warfarin sodium safely and effectively. See full prescribing information for warfarin sodium. Initial U.S. Approval: 1954

See full prescribing information for complete boxed warning.
WARNING: BLEEDING RISK
- **Warfarin sodium can cause major or fatal bleeding.(5)**
- **Perform regular monitoring of INR in all treated patients.(2.6).**
- **Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. (7)**
- **Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding. (17).**

RECENT MAJOR CHANGES
Warnings and Precautions, Use in Pregnant Women with Mechanical Heart Valves (5.3) 10/2014

INDICATIONS AND USAGE
Warfarin sodium tablets, USP are a vitamin K antagonist indicated for:
- Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (1)
- Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement(1)
- Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction (1)

Limitations of Use
Warfarin sodium tablets, USP have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage (1)

DOSAGE AND ADMINISTRATION
- Individualize dosing regimen for each patient, and adjust based on INR response (, 2.1, 2.2)
- Knowledge of genotype-assistance initiation selection. (2.3)
- Monitoring: Obtain daily INR determinations upon initiation until stable in the therapeutic range. Obtain subsequent INR determination every 1 to 4 weeks. (2.6)
- Review concomitant medications from other anticoagulants. (2.5)

DOSAGE FORMS AND STRENGTHS
- Scored tablets: 1, 2, 2.5, 3, 4, 5, 6, 7.5 or 10 mg (3)

CONTRAINDICATIONS
- Hypersensitivity to warfarin sodium tablets (4)
- Hemorrhagic tendencies or blood dyscrasias (4)
- Recent or contemplated surgery of the central nervous system (CNS) or eye, or traumatic surgery resulting in large exposed wound surfaces
- Bleeding tendencies associated with certain conditions (4)
- Threatened abortion, eclampsia, and preeclampsia (4
- Unsupervised patients with questionable levels of mental compliance (4
- Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding (4
- Malignant hypertension as a result of severe hypertensive crisis (4
- Major organ/tissue lumbar block anesthesia (4
- Malignant hypertension (4)

WARNINGS AND PRECAUTIONS
- Tissue necrosis: Necrosis or gangrene of skin or other tissues can occur, with severe cases requiring debridement or amputation, and rare reports of calciphylaxis. Discontinue warfarin sodium tablets immediately (5.2)
- Systemic atheroembolid and cholesterol microemboli: Some cases progressed to necrosis or death. Discontinue warfarin sodium if such embolization (5.5)
- Heparin-induced thrombocytopenia (HIT): Initial therapy with warfarin sodium in HIT has resulted in cases of amputation and death. Warfarin sodium may be considered after platelet count has normalized (5.6)
- Pregnancy: Warfarin sodium/fetal harm: Warfarin sodium may cause fetal harm; however, the benefits may outweigh the risks. (5.3)

ADVERSE REACTIONS
Most common adverse reactions to warfarin sodium are fatal and nonfatal hemorrhage from any tissue or organ. (6)
To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
- Consult labeling of all concurrently used drugs for complete information about interactions with warfarin sodium to increase risks for bleeding (7)
- Inhibitors: antibiotics, of CYP2C9, 1A2, or 3A4. May alter warfarin response. Monitor INR closely when any such drug is added or discontinued (7.1)
- Drugs that increase bleeding risks: Closely monitor patients receiving any such drug (e.g., other anticoagulants, antiplatelet agents, nonsteroidal antiinflammatory drugs, serotonin reuptake inhibitors) (7.2
- Antibiotics and antifungals: Closely monitor INR when initiating or stopping an antibiotic or antifungal course of therapy. (7.3)
- Botanical (herbal) products: Some may influence patient response to warfarin sodium so exercising close INR monitoring (7.4

USE IN SPECIFIC POPULATIONS
- Nursing mothers: Use with caution in a nursing woman. Monitor breastfeeding infants for bleeding or bleeding. (8.3)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.

Revised: 10/2014

FULL PRESCRIBING INFORMATION: CONTENTS*

WARNING: BLEEDING RISK
1. INDICATIONS AND USAGE
2. DOSAGE AND ADMINISTRATION
2.1 Individualized Dosing
2.2 Recommended Target INR Ranges and Durations for Individual Indications
2.3 Initial and Maintenance Dosing
2.4 Monitoring to Achieve Optimal Anticoagulation
2.5 Missed Dose
2.7 Treatment During Dentistry and Surgery
2.8 Conversion From Other Anticoagulants
3. DOSAGE FORMS AND STRENGTHS
4. CONTRAINDICATIONS
5. WARNINGS AND PRECAUTIONS
5.1 Hemorrhage
5.2 Tissue Necrosis
5.5 Systemic Atheroembolid and Cholesterol Microemboli
5.6 Heparin-Induced Thrombocytopenia
5.3 Use in Women with Mechanical Prosthetic Heart Valves
5.4 Females of Reproductive Potential
5.7 Other Clinical Settings with Increased Risks
5.8 Endogenous Factors Affecting INR
6. ADVERSE REACTIONS
7. DRUG INTERACTIONS
7.1 CYP450 Interactions
7.2 Drugs that Increase Bleeding Risk
7.3 Antibiotics and Antifungals
7.4 Botanical (Herbal) Products and Foods
8. USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.3 Nursing Mothers
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Renal Impairment
8.7 Hepatic Impairment
8.4 Females of Reproductive Potential
10. OVERDOSAGE
10.1 Signs and Symptoms
10.2 Treatment
11. DESCRIPTION
12. CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
12.5 Pharmacogenomics
13. NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14. CLINICAL STUDIES
14.1 Atrial Fibrillation
14.2 Mechanical and Bioprosthetic Heart Valves
14.3 Myocardial Infarction
15. REFERENCES
16. HOW SUPPLIED/STORAGE AND HANDLING
17. PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

WARNING: BLEEDING RISK
- **Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1)].**
- **Perform regular monitoring of INR in all treated patients [see Dosage and Administration (2.6)].**
- **Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy [see Drug Interactions (7)].**
- **Instruct patients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding [see Patient Counseling Information (17)].**

1. INDICATIONS AND USAGE

Warfarin sodium tablets, USP are indicated for:
- Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE).
- Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement.
- Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

Limitations of Use

Warfarin sodium tablets, USP have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage. Once a thrombus has occurred, however, the goals of anticoagulant treatment are to prevent further extension of the formed clot and to prevent secondary thromboembolic complications that may result in serious and possibly fatal sequelae.

2. DOSAGE AND ADMINISTRATION

2.1 Individualized Dosing

The dosage and administration of warfarin sodium must be individualized for each patient according to the patient's INR response to the drug. Adjust the dose based on the patient's INR and the condition being treated. Consult the latest evidence-based clinical practice guidelines from the American College of Chest Physicians (ACCP) to assist in the determination of the duration and intensity of anticoagulation with warfarin sodium [see *References (1)*]. 15

2.2 Recommended Target INR Ranges and Durations for Individual Indications

An INR of greater than 4 appears to provide no additional therapeutic benefit in most patients and is associated with a higher risk of bleeding.

Venous Thromboembolism (including deep venous thrombosis [DVT] and PE)

Adjust the warfarin dose to maintain a target INR of 2.5 (INR range, 2 to 3) for all treatment durations. The duration of treatment is based on the indication and risk factors.
- For patients with a DVT or PE secondary to a transient (reversible) risk factor, treatment with warfarin for 3 months is recommended.
- For patients with an unprovoked DVT or PE, treatment with warfarin is recommended for at least 3 months. After 3 months of therapy, evaluate the risk-benefit ratio of long-term treatment for the individual patient.
- For patients with two episodes of unprovoked DVT or PE, long-term treatment with warfarin is recommended for a patient receiving long-term anticoagulant treatment, periodically reassess the risk/benefit ratio of continuing such treatment in the individual patient.

Atrial Fibrillation

In patients with non-valvular AF, anticoagulate with warfarin to target INR of 2.5 (range, 2 to 3).
- In patients with non-valvular AF that is persistent or paroxysmal and at high risk of stroke (i.e., having any of the following features: prior ischemic stroke, transient ischemic attack, or systemic embolism; age greater than 75 years; hypertension; diabetes mellitus; moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus), long-term anticoagulation with warfarin is recommended.
- In patients with non-valvular AF that is persistent or paroxysmal and at an intermediate risk of ischemic stroke (i.e., having 1 of the following risk factors: age greater than 75 years, moderately or severely impaired left ventricular systolic function and/or heart failure, history of hypertension, or diabetes mellitus), long-term anticoagulation with warfarin is recommended.
- For patients with AF and a prosthetic heart valve, long-term anticoagulation with warfarin is recommended.
- For patients with AF and prosthetic heart valves, long-term anticoagulation with warfarin is recommended; the target INR may be increased and aspirin added depending on valve type and position, and on patient factors.

Mechanical and Bioprosthetic Heart Valves
- For patients with bileaflet mechanical valve or a Medtronic Hall (Minneapolis, MN) tilting disk valve in the mitral position, without atrial fibrillation and without left atrial enlargement, therapy with warfarin to a target INR of 2.5 (range, 2 to 3) is recommended.
- For patients with tilting disk valves and bileaflet mechanical valves in the mitral position, therapy with warfarin to a target INR of 3 (range, 2.5 to 3.5) is recommended.
- For patients with caged ball or caged disk valves, therapy with warfarin to a target INR of 3 (range, 2.5 to 3.5) is recommended.
- For patients with a bioprosthetic valve in the mitral position, therapy with warfarin to a target INR of 2.5 (range, 2 to 3) is recommended. For patients with a bioprosthetic valve and additional risk factors for thromboembolism are present (AF, previous thromboembolism, left ventricular dysfunction), a target INR of 2.5 (range, 2 to 3) is recommended.

Post-Myocardial Infarction

For patients with recent MI (e.g., those with a large anterior MI, those with significant heart failure, those with intracardiac thrombus visible on transthoracic echocardiography, those with AF, and those with a history of a thromboembolic event), therapy with combined moderate-intensity (INR, 2 to 3) warfarin plus low-dose aspirin (i. 100 mg/day) for at least 3 months after the MI is recommended.

Recurrent Systemic Embolism and Other Indications

Oral anticoagulation therapy with warfarin has not been fully evaluated by clinical trials in patients with valvular disease associated with AF, patients with mitral stenosis, and patients with recurrent systemic embolism of unknown etiology. However, a moderate dose regimen (INR 2 to 3) may be used for these patients.

2.3 Initial and Maintenance Dosing

The appropriate initial dosing of warfarin sodium varies widely for different patients. Not all factors responsible for warfarin dose variability are known, and the initial dose is influenced by:
- Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities
- Genetic factors (CYP2C9 and VKORC1 genotypes) [see *Clinical Pharmacology (12.5*.

Select the initial dose based on the expected maintenance dose, taking into account the above factors. Modify this dose based on consideration of patient-specific clinical factors. Consider lower initial and maintenance doses for elderly and/or debilitated patients and in Asian patients [see and Routine use of loading doses is not recommended in this practice may increase hemorrhage and other complications and does not offer more rapid protection against clot formation. *Use in Specific Populations (*.8.5*Clinical Pharmacology (). 12.3*

Individualize the duration of therapy for each patient. In general, anticoagulate therapy should be continued until the danger of thrombosis and embolization *passed [see Dosage and Administration ()*. *2.2*

Dosing Recommendations without Consideration of Genotype

If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium is usual 2 to 5 mg once daily. Determine each patient's dosing needs by close monitoring of the INR response and consideration of the indication being treated. Typical maintenance doses are 2 to 10 mg once daily.

Dosing Recommendations with Consideration of Genotype

Table 1 displays three ranges of expected maintenance warfarin sodium doses observed in subgroups of patients having different combinations of CYP2C9 and VKORC1 gene variants [see If the patient's CYP2C9 and/or VKORC1 genotype are known, consider these ranges in choosing the initial dose. Patients with CYP2C9 *1/*3, *2/*3, *2/*2, and *3/*3 may require more prolonged time (> 2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen than patients without these CYP variants. *Clinical Pharmacology ( ). 12.5*

Table 1Three Ranges of Expected Maintenance Warfarin Sodium Daily Doses Based on CYP2C9 and VKORC1 Genotypes †

	CYP2C9						
VKORC1	*1/*1	*1/*2	*1/*3	*2/*2	*2/*3	*3/*3
GG	5-7 mg	5-7 mg	3-4 mg	3-4 mg	0.5-2 mg	0.5-2 mg
AG	3-4 mg	3-4 mg	0.5-2 mg	0.5-2 mg	0.5-2 mg	0.5-2 mg
AA	0.5-2 mg	0.5-2 mg	0.5-2 mg	0.5-2 mg	0.5-2 mg	0.5-2 mg

Ranges are derived from multiple published clinical studies. *VKORC1 -1639G>A genotype is a powerful predictor of warfarin sensitivity. Other variants in VKORC1 contribute to the observed variability in warfarin dose, but are not as powerful as the -1639G>A variant. Other cofactors affecting warfarin response may also be important determinants of warfarin dose.*

2.4 Monitoring to Achieve Optimal Anticoagulation

Warfarin sodium is a narrow therapeutic range (index) drug, and its actions may be affected by factors such as other drugs and dietary vitamin K. Therefore, anticoagulation must be carefully monitored during warfarin sodium therapy. Determine the INR daily after the administration of the initial dose until the INR response to the dose is established. Base subsequent dosing and the frequency of monitoring on the range by performing periodic INRs. The frequency of performing INR should be based on the clinical situation but generally acceptable intervals for INR determination are 1 to 4 weeks. Perform additional INR tests when other warfarin products are interchanged with warfarin sodium, as well as whenever other medications are initiated, discontinued, or taken irregularly. Heparin, a common concomitant drug, increases the INR [see and *Dosage and Administration ( ).2.8Drug Interactions ( ). 7*

Determination of whole blood clotting and bleeding times are not effective measures for monitoring of warfarin sodium therapy.

2.5 Missed Dose

The anticoagulant effect of warfarin sodium persists beyond 24 hours. If a patient misses a dose of warfarin sodium at the intended time of day, the patient should take the dose as soon as possible on the same day. The patient should not double the dose the next day to make up for a missed dose.

2.7 Treatment During Dentistry and Surgery

Some dental or surgical procedures may necessitate the interruption or change in the dose of warfarin sodium therapy. Consider the benefits and risks when discontinuing warfarin sodium even for a short period of time. Determine the INR immediately prior to any dental or surgical procedure. In patients undergoing minor procedures, a single dose of vitamin K administered 12 to 24 hours after, immediately following these procedures, adjusting the dosage of warfarin sodium to maintain the INR at the low end of the therapeutic range may safely allow for continued anticoagulation.

2.8 Conversion From Other Anticoagulants

Heparin

Since the full anticoagulant effect of warfarin sodium is not achieved for several days, heparin is preferred for initial rapid anticoagulation. During initial therapy with warfarin sodium, the interference with heparin anticoagulation is of minimal clinical significance. Conversion to warfarin sodium may begin concomitantly with heparin therapy within 3 to 5 days. To ensure therapeutic anticoagulation, continue full dose heparin therapy and overlap warfarin sodium therapy with heparin for 4 to 5 days and until warfarin sodium has produced the desired therapeutic response as determined by INR, at which point heparin may be discontinued.

As heparin may affect the INR, patients receiving both heparin and warfarin sodium should have INR monitoring at least:
- 5 hours after the last intravenous bolus dose of heparin, or
- 4 hours after cessation of a continuous intravenous infusion of heparin, or
- 24 hours after the last subcutaneous heparin injection.

Warfarin sodium may increase the activated partial thromboplastin time (aPTT) test, even in the absence of heparin. A severe elevation (> 50 seconds) in aPTT with an INR in the desired range has been identified as an indication of increased risk of postoperative hemorrhage.

Other Anticoagulants

Consult the labeling of other anticoagulants for instructions on conversion to warfarin sodium.

3. DOSAGE FORMS AND STRENGTHS

- 1 mg are pink, oval, flat, beveled edge, uncoated tablets debossed with the logo of "WAR", "1" and bisect on one side and plain on other side.
- 2 mg are tan, oval, flat, beveled edge, uncoated tablets debossed with the logo of "WAR", "2" and bisect on one side and plain on other side.
- 2.5 mg are green, oval, flat, beveled edge, uncoated tablets debossed with the logo of "WAR", "2½" and bisect on one side and plain on other side.
- 3 mg are tan, oval, flat, beveled edge, uncoated tablets debossed with the logo of "WAR", "3" and bisect on one side and plain on other side.
- 4 mg are blue, oval, flat, beveled edge, uncoated tablets debossed with the logo of "WAR", "4" and bisect on one side and plain on other side.
- 5 mg are peach, oval, flat, beveled edge, uncoated tablets debossed with the logo of "WAR", "5" and bisect on one side and plain on other side.
- 6 mg are red, oval, flat, beveled edge, uncoated tablets debossed with the logo of "WAR", "6" and bisect on one side and plain on other side.
- 7.5 mg are yellow, oval, flat, beveled edge, uncoated tablets debossed with the logo of "WAR", "7½" and bisect on one side and plain on other side.
- 10 mg are white to off white, oval, flat, beveled edge, uncoated tablets debossed with the logo of "WAR", "10" and bisect on one side and plain on other side.

4. CONTRAINDICATIONS

- **Pregnancy**

Warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism[Warfarin sodium tablets can cause fetal harm when administered to a pregnant woman. Warfarin sodium tablets exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If warfarin sodium tablets are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus *[see and see Warnings and Precautions ( )and Use in Specific Populations ( )]. 5.8Warnings and Precautions ( ) 5.6Use in Specific Populations ( ). 8.1*

- Hemorrhagic tendencies or blood dyscrasias
- Recent or contemplated surgery of the central nervous system or eye, or traumatic surgery resulting in large open surfaces *[see Warnings and Precautions ( ). 5.7*
- Bleeding tendencies associated with:
  - Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tract
  - Central nervous system hemorrhage
  - Cerebral aneurysm, dissecting aorta
  - Pericarditis and pericardial effusion
  - Bacterial endocarditis
- Threatened abortion, eclampsia, and preeclampsia
- Unsupervised patients with conditions associated with potential high level of non-compliance
- Spinal puncture and other diagnostic or therapeutic procedures with potential for uncontrollable bleeding
- Hypersensitivity to warfarin or to any other components of this product (e.g., anaphylaxis) *[see Adverse Reactions( )]. 6*
- Major regional or lumbar block anesthesia
- Malignant hypertension

5. WARNINGS AND PRECAUTIONS

5.1 Hemorrhage

Warfarin sodium can cause major or fatal bleeding. Bleeding is more likely to occur within the first month. Risk factors for bleeding include high intensity of anticoagulation(INR > 4), age greater than or equal to 65, history of highly variable INRs, history of gastrointestinal bleeding, hypertension, cerebrovascular disease, renal failure, anemia, and bleeding with previous oral anticoagulant therapy, and certain concomitant drugs *[see and long duration of warfarin therapy. Clinical Pharmacology ( ). 12.5Drug Interactions( ). 7]*

Perform regular monitoring of INR in all treated patients. These at high risk of bleeding may benefit from more frequent INR monitoring, careful dose adjustments to desired INR, and a shorter duration of therapy appropriate for the clinical condition. However, maintenance of INR in the therapeutic range does not eliminate the risk of bleeding.

Drugs, dietary changes, and other factors affect INR levels achieved with warfarin sodium therapy. Performfrequent INR monitoring when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs *[see Drug Interactions ( ). 7*

Instructpatients about prevention measures to minimize risk of bleeding and to report signs and symptoms of bleeding *[see Patient Counseling Information ( ). 17*

5.2 Tissue Necrosis

Necrosis and/or gangrene of skinand other tissues is an uncommon but serious risk (< 0.1%). Necrosis has been associated with local thrombosis and usually appears within few days of the start of warfarin sodiumtherapy. In severe cases of necrosis, treatment through debridement or amputation of the affected tissue, limb, breast, or penis has been reported.

Careful clinical evaluation is required to determine whether necrosis is caused by an underlying disease. Although various treatments have beenattempted, no treatment for necrosis has been considered uniformly effective. Discontinue warfarin sodiumtherapy if necrosis occurs. Consider alternative drugs if continued anticoagulation therapy is necessary.

5.3 Systemic Atheroembolli and Cholesterol Microembolli

Anticoagulation therapy with warfarin sodium may enhance the release of atheromatous plaque emboli. Systemic atheroembolli and cholesterol microembolli can present with a variety of signs and symptoms depending on the site of embolization. The most commonly involved visceral organs are the kidneys followed by the pancreas, spleen, and liver. Some cases have progressed to necrosis or death. A distinct syndrome resulting from microembolli to the feet is known as "purple toes syndrome". Discontinue warfarin sodiumtherapy if such phenomena are observed. Consider alternative drugs if continued anticoagulation therapy is necessary.

5.4 Heparin-Induced Thrombocytopenia

Do not use warfarin sodium as initial therapy in patients with heparin-induced thrombocytopenia (HIT) and with heparin-induced thrombocytopenia with thrombosis syndrome (HITTS). Cases of limb ischemia, necrosis, and gangrene have occurred in patients with HIT and HITTS when heparin treatment was discontinued and warfarin therapy was started or continued. Instate patients, sequelae have included amputation of the involved area and/or death. Treatment with warfarin sodium may be considered after the platelet count has normalized.

5.5 Use in Pregnant Women with Mechanical Heart Valves

Warfarin sodium can cause fetal harm when administered to a pregnant woman. While warfarin sodium is contraindicated during pregnancy, the potential benefits of using warfarin sodium may outweigh the risks for pregnant women with mechanical heart valves at high risk of thromboembolism. In these individual situations, the decision to initiate or continue warfarin sodium should be reviewed with the patient and a cardiac specialist, taking into account the patient's preferences, the specifics of the medical situation, as well as the most current medical guidelines. Warfarin sodium exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus *[see Use in Specific Populations ( ). 8.1*

5.6 Females of Reproductive Potential

Warfarin sodium exposure during pregnancy can cause pregnancy loss, birth defects, or fetal death. Discuss pregnancy planning with females of reproductive potential who are on warfarin sodium therapy *[see and Contraindications ( ) 4Use in Specific Populations ( ). 8.6*

5.7 Other Clinical Settings with Increased Risks

Inthe following clinical settings, the risk of warfarin sodium therapy may be increased:

- Moderate to severe hepatic impairment
- Infectious diseases or disturbances of intestinal flora (e.g., sprue, antibiotic therapy)
- Severe renal impairment
- Severe to moderate hypertension
- Deficiency in protein C-mediated anticoagulant response: Warfarin sodium reduces the synthesis of the naturally occurring anticoagulant, protein C, and protein S. Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. Concomitant anticoagulation therapy with heparin for 5 to 7 days during initiation of therapy with warfarin sodium may minimize the incidence of tissue necrosis in these patients.
- Surgery or other procedures: Consider temporarily withholding warfarin sodium for a short time in minor complications of sharp needle and local anesthesia block but not associated with potentially slight-threatening operative hemorrhagic complications. As warfarin sodium cessation or reduction may lead to serious thromboembolic complications, the decision to discontinue warfarin sodium before a relatively less invasive and complex eye surgery, such as lens surgery, should be based upon the risks of anticoagulant therapy weighed against the benefits.
- Polycythemia vera
- Malignancy
- Diabetes mellitus

5.8 Endogenous Factors Affecting INR

The following factors may be responsible for INR response: diarrhea, hepatic disorders, poor nutritional status, steatorrhea, or vitamin K deficiency: **increased**

The following factors may be responsible for INR response: increased vitamin K intake or hereditary warfarin resistance: **decreased**

6. ADVERSE REACTIONS

The following serious adverse reactions to warfarin sodium are discussed in greater detail in other sections of the labeling:

- Hemorrhage *[see , and Bleed WarningWarnings and Precautions ( ). 5.1Overdosage ( ) 10*
- Necrosis of skinand other tissues *[see* Warnings and Precautions *( ) 5.2*
- Systemic atheroembolli and cholesterol microembolli *[see* Warnings and Precautions *( ) 5.3*
- Other adverse reactions to warfarin sodium include:
- Immune system disorders: hypersensitivity/allergic reactions (including urticaria and anaphylactic reactions)
- Vascular disorders: vasculitis
- Hepatobiliary disorders: hepatitis elevated liver enzymes. Cholestatic hepatitis has been associated with concomitant administration of warfarin sodium and nicoguilon.
- Gastrointestinal disorders: nausea, vomiting, diarrhea, taste perversion, abdominal pain, flatulence, bloating
- Skin disorders: rash, dermatitis (including bullous eruptions), pruritus, alopecia
- Respiratory disorders: tracheal or tracheobronchial calcification
- General disorders: chills

7. DRUG INTERACTIONS

Drugs may interact with warfarin sodium through pharmacodynamic or pharmacokinetic mechanism. Pharmacodynamic mechanisms for drug interactions with warfarin sodium are synergism (impaired hemostasis), competition for vitamin K, and competition for warfarin sodium binding sites or inhibition of the physiologic control loop for vitamin K metabolism (hereditary resistance). Pharmacokinetic mechanisms for drug interactions with warfarin sodium are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding. It is important to note that some drugs may interact by more than one mechanism.

More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-treatment (e.g., antibiotics, antifungals, cimicoxib)*[see). Bleed Warning*

Consultthe labeling of all concurrently used drugs to obtain further information about interactions with warfarin sodium or adverse reaction pertaining to bleeding.

7.1 CYP450 Interactions

CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4. The stereoisomer warfarin-enantiomer is metabolized by CYP2C9 while the –enantiomer is metabolized by CYP2C19, 2C8, and 3A4.

- Inhibitors of CYP2C9, 1A2, and/or 3A4 have the potential to increase the effect (decrease INR) of warfarin by increasing the exposure of warfarin.
- Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect (decrease INR) of warfarin by decreasing the exposure of warfarin.

Examples of inhibitors and inducers of CYP2C9, 1A2, and 3A4 are below in Table 2; however, this list should not be considered all-inclusive. Consult the labeling of all concurrently used drugs to obtain further information about CYP450 interaction potential. The CYP450 inhibition and induction potential should be considered when starting, stopping, or changing dose of concomitant medications. Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer.

Table 2 Examples of CYP450 Interactions with Warfarin

Enzyme	Inhibitors	Inducers
CYP2C9	amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, sertralineae, sulfinpyrazone, tigecycline, voriconazole, sulfinbazi	carbamazepine, barbiturates, rifampicin
CYP1A2	ciprofloxacin, alloquinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, fluvoxamine, fluoroquinolones, propafenone, propranolol, ticlopidine, thiabendazole, tacrine, verapamil, zileuton	carbamazepine, omeprazole, phenobarbital, phenytoin, cigarette smoking
CYP3A4	ritonavir, amiodarone, amiodarone, aprepitant, aprepitant, atorvastatin, atorvastatin, bicalutamide, clotrimazol, cimetidine, ciprofloxacin, ciprofloxacin, cyclosporine, danazol/ritonavir, diltiazem, erythromycin, fluconazole, fluvoxamine, fosaprepitant, imatinib, isoniazid, lansoprazole, lansoprazole, levofloxacin, macrolides, metronidazole, miconazole, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranitidine, ritonavir, saquinavir, telithromycin, tipranavir, voriconazole, vitamin	barbiturates, carbamazepine, efavirenz, etravirine, modafinil, nelfinavir, phenytoin, pioglitazone, prednisone, rifampin, rifamycin

7.2 Drugs that Increase Bleeding Risk

Examples of drugs known to increase the risk of bleeding are presented in Table 3. Because bleeding risk is increased when these drugs are used concomitantly with warfarin, *closely* monitor patients receiving any such drug with warfarin.

Table 3Drugs that Can Increase the Risk of Bleeding

Drug Class	Specific Drugs
Anticoagulants	argatroban, dabigatran, bivalirudin, dextrans, heparin, tepirudin
Platelet Aggregation Inhibitors	cilostazol, clopidogrel, dipyridamole, ticlopidine, prasugrel, ticagrelor
Nonsteroidal Anti-inflammatory Agents	celecoxib, diclofenac, diflunisal, etoposides, ibuprofen, indomethacin, ketoprofen, ketorolac, meloxicam, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac
Serotonin Reuptake Inhibitors	citalopram, escitalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, sertraline, paroxetine, venlafaxine, vilazodone

7.3 Antibiotics and Antifungals

There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin.

Closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking warfarin.

7.4 Botanical (Herbal) Products and Foods

Exercise caution when botanical (herbal) products are taken concomitantly with warfarin sodium. Few adequate, well-controlled studies evaluating the potential for metabolic and/or pharmacologic interaction between botanicals and warfarin sodium exist. Due to a lack of manufacturing standardization, the composition of botanicals may vary from batch to batch and from country to country. This could further confound the ability to assess potential interactions and effects on anticoagulation.

Some botanicals may cause bleeding events when taken alone (e.g., garlic and Ginkgo biloba) and may have anticoagulant, antiplatelet, and/or fibrinolytic properties. These effects would be expected to be additive to the anticoagulant effects of warfarin sodium. Conversely, some botanicals may decrease the effects of warfarin sodium(e.g., co-enzyme Q, St. John's wort ginseng). Some botanicals and foods can interact with warfarin sodium through CYP450 interactions (e.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. John's wort). ,,

Monitor the patient's response with additional INR determinations when initiating or discontinuing any botanicals.

8. USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

For women with mechanical heart valves *[see* and for other pregnant populations *[see* **Pregnancy Category B***Warnings and Precautions ( ) 5.5***Pregnancy Category X***Contraindications ( ). 4*

Warfarin sodium tablets are contraindicated in women who are pregnant except in pregnant women with mechanical heart valves, who are at high risk of thromboembolism. Warfarin sodium tablets can cause fetal harm when administered to a pregnant woman. Warfarin sodium tablets exposure during pregnancy causes a recognized pattern of major congenital malformations (warfarin embryopathy and fetotoxicity), fatal fetal hemorrhage, and an increased risk of spontaneous abortion and fetal mortality. The reproductive and developmental effects of warfarin sodiumthave not been evaluated in animals. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

Inhumans, warfarin crosses the placenta, and concentrations in fetal plasma approach the maternal plasma concentrations. Warfarin sodium is a teratogenic drug causing a recognizable pattern of malformations in about 5% of exposed offspring. Warfarin embryopathy is characterized by nasal hypoplasia with or without stippled epiphyses (chondrodysplasia punctata) and growth retardation (including low birth weight). Central nervous system and eye abnormalities have also been reported, including dorsal midline dysplasia characterized by agenesis of the corpus callosum, Dandy-Walker malformation, ventriculomegaly, optic nerve hypoplasia, microphthalmia, cataracts, and optic atrophy. Mental retardation, blindness, schizencephaly, microcephaly, hydrocephalus, and other adverse pregnancy outcomes have been reported following warfarinexposure during the second and third trimesters of pregnancy *[see and Contraindications ( )Warnings and Precautions ( ). 5.6*

8.3 Nursing Mothers

Based on published data in 15 nursing mothers, warfarin was not detected in human milk. Among the 15 nursing mothers, one infant was reported to have prolonged prothrombin time after ingesting milk. Prothrombin times were not obtained for the other 9 nursing infants. Monitor breastfeeding infants for bruising or bleeding. Effects in premature infants have not been evaluated. Caution should be exercised when warfarin sodium is administered to a nursing woman.

8.4 Pediatric Use

Adequate and well-controlled studies with warfarin sodium have not been conducted in any pediatric population, and the optimum dosing, safety, and efficacy in pediatric patients is unknown. Pediatric use of warfarin sodium is based on adult data and recommendations, and available limited pediatric data from prospective and retrospective studies. Children administered warfarin sodium should avoid any activity or sport that may result in traumatic injury.

The developing hemostatic system in infants and children results in a changing physiology of thrombosis and response to anticoagulant. Dosing of warfarin in the pediatric population varies by patient age, with infants generally having the highest, and adolescents having the lowest milligrams per kilogram dose requirements to maintain target INRs. Because of changing warfarin requirements due to age, concomitant medications, diet, and existing medical conditions, target INR ranges may be difficult to achieve and maintain in pediatric patients, and there frequent INR determinations are recommended. Bleeding rates varied by patient population and clinical care center in pediatric observational studies and patient registries.

Infants and children receiving vitamin K-supplemented nutrition, including infant formulas, may be resistant to warfarin therapy, while human milk-fed infants may be sensitive to warfarin therapy.

8.5 Geriatric Use

Of the total number of patients receiving warfarin sodium in controlled clinical trials for which data were available for analysis, 1885 patients (26.4%) were 65 years and older, while 185 patients (2.4%) were 75 years and older. No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Patients 60 years or older appear to exhibit greater than expected INR response to the anticoagulant effects of warfarin *[see* Warfarin sodiumtablets are contraindicated in any unsupervised patient with dementia or other cognitive impairment. Warfarin sodium should be used with extreme caution in patients with any physical condition where added risk of hemorrhage is present. Consider lower initiation and maintenance doses of warfarin sodium in elderly patients *[see Clinical Pharmacology ( ). 12.3Dosage and Administration ( ). 2.2-2.3*

8.6 Renal Impairment

Renal clearance is considered to be a minor determinant of anticoagulant response to warfarin. No dosage adjustment is necessary for patients with *renal* impairment.

8.7 Hepatic Impairment

Hepatic impairment can potentiate the response to warfarin through impaired synthesis of clotting factors and decreased metabolism of warfarin. Use caution when using warfarin sodium in these patients.

8.8 Females of Reproductive Potential

Warfarin sodium exposure during pregnancy can cause spontaneous abortion, birth defects, or fetal death. Discuss pregnancy planning with females of reproductive potential who are on warfarin sodium therapy, counseled regarding the benefits of therapy and potential reproductive risks. Discuss pregnancy planning with females of reproductive potential who are on warfarin sodium therapy. If the patient becomes pregnant while taking warfarin sodium, she should be apprised of the potential risks to the fetus.

10. OVERDOSAGE

10.1 Signs and Symptoms

Bleeding (e.g., appearance of blood in stools or urine, hematuria, excessive menstrual bleeding, melena, petechiae, excessive bruising or persistent oozing from superficial injuries, unexplained fall in hemoglobin) is a manifestation of excessive anticoagulation.

10.2 Treatment

The treatment of excessive anticoagulation is based on the level of the INR, the presence or absence of bleeding, and clinical circumstances. Reversal of warfarin sodium anticoagulation may be obtained by discontinuing warfarin sodium therapy and, if necessary, by administration of oral or parenteral vitamin K_{1}.

The use of vitamin K reduces response to subsequent warfarin sodium therapy and patients may return to a pretreatment thrombotic status following the rapid reversal of a prolonged INR. Resumption of warfarin sodium therapy shortens or reverses the effect of vitamin K, and a therapeutic INR can again be obtained by careful dosage adjustment. If rapid re-anticoagulation is indicated, heparin may be preferable for initial therapy.

Prothrombin complex concentrate (PCC), fresh frozen plasma or activated Factor VII treatment may be considered if the requirement to reverse the effects of warfarin sodium is urgent. A risk of hepatitis and other viral diseases is associated with the use of blood products; PCC and activated Factor VII are also associated with an increased risk of thrombosis. Therefore, these preparations should be used only in exceptional or life-threatening bleeding episodes secondary to warfarin sodium overdosage.

11. DESCRIPTION

Warfarin sodium is an anticoagulant that acts by inhibiting vitamin K-dependent coagulation factors. Chemically, it is 3-(α-acetonylbenzyl)-4-hydroxycoumarin and is a racemic mixture of the - and -enantiomers. Crystalline warfarin sodium is an isopropanol clathrate. Its molecular formula is C H NaO , and its structural formula is represented by the following: M_{r}=330.34



Warfarin sodium, USP is a white crystalline powder. It is very soluble in water.

Each warfarin sodium tablet intended for oral administration contains warfarin sodium clathrate equivalent to 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg or 15 mg of warfarin sodium. In addition each tablet contains the inactive ingredients hydroxypropyl cellulose, lactose monohydrate, magnesium stearate and pregelatinized starch. Additionally each 1 mg tablet contains D&C red no. 6 barium lake, 2 mg tablet contains FD&C blue no. 2 aluminum lake and FD&C red no. 40 aluminum lake, 2.5 mg tablet contains D&C yellow no. 10 aluminum lake and FD&C blue no. 1 aluminum lake, 3 mg tablet contains FD&C yellow no. 6 aluminum lake, FD&C blue no. 2 aluminum lake and FD&C red no. 40 aluminum lake, 4 mg tablet contains FD&C blue no. 1 aluminum lake, 5 mg tablet contains D&C yellow no. 10 aluminum lake, 6 mg tablet contains FD&C yellow no. 6 aluminum lake and FD&C blue no. 1 aluminum lake, 7.5 mg tablet contains D&C yellow no. 10 aluminum lake and FD&C yellow no.6 aluminum lake and 10 mg tablet is dye free.

12. CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Warfarin acts by inhibiting the synthesis of vitamin K-dependent clotting factors, which include Factors II, VII, IX, and X, and the anticoagulant proteins C and S. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K-dependent clotting factors. Vitamin K promotes the biosynthesis of γ-carboxyglutamic acid residues in the proteins that are essential for biological activity. Warfarin is thought to exert its effect by blocking the enzyme by inhibition of the 2,3 subunit of vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K epoxide [see *Clinical Pharmacology (.)*]. *12.5*

12.2 Pharmacodynamics

An anticoagulation effect generally occurs within 24 hours after warfarin administration. However, peak anticoagulant effect may be delayed 72 to 96 hours. The duration of action of a single dose of warfarin is dose-dependent. The effect on prothrombin time, a measure of the anticoagulant effects of daily maintenance doses overlap. This is consistent with the half-lives of the affected vitamin K-dependent clotting factors and anticoagulant proteins: Factor II - 60 hours, VII - 4 to 6 hours, IX - 24 hours, X - 48 to 72 hours, and proteins C and S are approximately 8 hours and 30 hours, respectively.

12.3 Pharmacokinetics

Warfarin sodium is a racemic mixture of the - and -enantiomers of warfarin. The -enantiomer exhibits 2 to 5 times more anticoagulant activity than the -enantiomer isomer, but generally has a more rapid clearance. *BSR*

Absorption

Warfarin is essentially completely absorbed after oral administration, with peak concentration generally attained within the first 4 hours.

Distribution

Warfarin distributes into a relatively small apparent volume of distribution of about 0.14 L/kg. A distribution phase lasting 6 to 12 hours is distinguishable after oral administration of an aqueous solution. Approximately 99% of the drug is bound to plasma proteins.

Metabolism

The eliminations of warfarin is almost entirely by metabolism. Warfarin is stereoselectively metabolized by hepatic cytochrome P-450 (CYP450) microsomal enzymes to inactive hydroxylated metabolites (predominant route) and by reductases to reduced metabolites (warfarin alcohols) with minimal contribution to the anticoagulant activity of warfarin. Reduction of the ketone moiety of the -enantiomer alcohols, and 4′-, 6-, 7-, 8- and 10-hydroxywarfarin. The CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C18, 2C8, 2C19, 1A2, and 3A4. CYP2C9, a polymorphic enzyme, is likely to be the principal form of human liver CYP450 that mediates the anticoagulant activity of warfarin. Patients with one or more variant CYP2C9 alleles have decreased S-warfarin clearance [see *in vivo Clinical Pharmacology (.)*]. *12.5*

Excretion

The terminal half-life of warfarin after a single dose is approximately 1 week; however, the effective half-life ranges from 20 to 60 hours, with a mean of about 40 hours. The clearance of R-warfarin is generally half that of S-warfarin, thus as the volumes of distribution are similar, the half-life of R-warfarin is longer than that of S-warfarin. The half-life of R-warfarin ranges from 37 to 89 hours, with a mean of approximately 60 hours. The half-life of S-warfarin ranges from 21 to 60 hours. Unchanged drug have demonstrated that up to 92% of the orally administered dose is recovered in urine. Very little warfarin is excreted unchanged in urine. Urinary excretion is in the form of metabolites.

Geriatric Patients

Patients 65 years or older appear to exhibit greater than expected INR response to the anticoagulant effects of warfarin. The cause of the increased sensitivity to the anticoagulant effects of warfarin in this age group is unknown but may be due to a combination of pharmacokinetic and pharmacodynamic factors. Limited information suggests there is no difference in the clearance of S-warfarin; however, there may be a slight decrease in the clearance of R-warfarin in the elderly as compared to the young. Therefore, as patient age increases, a lower dose of warfarin is usually required to produce a therapeutic level of anticoagulation [see *Dosage and Administration (.)*]. *2.3,2.4*

Asian Patients

Asian patients may require lower initiation and maintenance doses of warfarin. A non-controlled study of 151 Chinese outpatients stabilized on warfarin for various indications reported a mean daily warfarin requirement of 3.3 ± 1.4 mg to achieve an INR of 2 to 2.5. Patient age was the most important determinant of warfarin requirement in these patients, with a progressively lower warfarin requirement with increasing age.

12.5 Pharmacogenomics

CYP2C9 and VKORC1 Polymorphisms

The -enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles, CYP2C9*2 and CYP2C9*3, result in decreased CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively. *In vitro*

Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9, and *11 alleles in Caucasians.

Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle through inhibition of VKOR, a multiprotein enzyme complex. Certain single nucleotide polymorphisms in the VKORC1 gene (e.g., −1639G>A) have been associated with variable warfarin dose requirements. CYP2C9 and VKORC1 gene variants generally explain the largest proportion of known variability in warfarin dose requirements.

CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the initial dose of warfarin [see *Dosage and Administration (.)*]. *2.3*

13. NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, or fertility studies have not been performed with warfarin.

14. CLINICAL STUDIES

14.1 Atrial Fibrillation

In five prospective, randomized, controlled clinical trials involving 3711 patients with non-rheumatic AF, warfarin significantly reduced the risk of systemic thromboembolism including stroke [see Table 4]. The risk reduction ranged from 60% to 86% in all except one trial (CAFA: 45%), which was stopped early due to published positive results from two of these trials. The incidence of major bleeding in these trials ranged from 0.6% to 2.7% [see Table 4].

Table 4Clinical Studies of Warfarin in Non-Rheumatic AF Patients*

Study	N		Thromboembolism				% Major Bleeding	
	Warfarin-Treated Patients	Control Patients	PT Ratio[INR]	% Risk Reduction	p-value	Warfarin-Treated Patients	Control Patients
SPAFII	335	336	1.5-2.3	60	0.017	0.6	0
SPAF	210	211	1.3-1.8	67	0.01	1.8	1.9
BAATAF	212	208	1.2-1.5	86	<0.05	0.9	0.5
CAFA	187	191	1.3-1.6	45	0.25	2.7	0.5
SPINAF	260	265	1.2-1.5	79	0.001	2.3	1.5

* All study results of warfarin vs. control are based on intention-to-treat analysis and include ischemic stroke and systemic thromboembolism, excluding hemorrhagic stroke and transient ischemic attacks.

Trials in patients with both AF and mitral stenosis suggest a benefit from anticoagulation with warfarin sodium [see *Dosage and Administration (.)*]. *2.2*

14.2 Mechanical and Bioprosthetic Heart Valves

In a prospective, randomized, open-label, positive-controlled study in 254 patients with mechanical prosthetic heart valves, the thromboembolic-free interval was found to be significantly greater in patients treated with warfarin alone compared with dipyridamole/aspirin-treated patients (p=0.002) and potentially fewer in-treated patients (p=0.01). The results of this study are presented in Table 5.

Table 5Prospective, Randomized, Open-Label, Positive-Controlled Clinical Study of Warfarin in Patients with Mechanical Prosthetic Heart Valves

		Patients Treated With	
Event	Warfarin	Dipyridamole/Aspirin	Dipyridamole/Aspirin
Thromboembolism	2/100 py	6/100 py	5/100 py
Major Bleeding	1/100 py	1/100 py	1/100 py

py=patient years

In a prospective, open-label, clinical study comparing moderate (INR 2-4.5) vs. high intensity (INR 9) warfarin therapies in 258 patients with mechanical prosthetic heart valves, thromboembolism occurred with similar frequency in the two groups (4 and 3.7 events per 100 patient years, respectively). Major bleeding was more common in the high intensity group. The results of this study are presented in Table 6.

Table 6Prospective, Open-Label Clinical Study of Warfarin in Patients with Mechanical Prosthetic Heart Valves

Event	Moderate Warfarin Therapy INR 2-4.5	High Intensity Warfarin Therapy INR 9
Thromboembolism	4/100 py	3.7/100 py
Major Bleeding	0.9/100 py	1.1/100 py

py=patient years

In a randomized trial in 210 patients comparing two intensities of warfarin therapy (INR 2 to 2.25 vs. INR 2.8 to 4.8) in patients with mechanical heart valves, thromboembolic events (including stroke) occurred with similar frequency in the two groups (major embolic events 2.% vs. 1.8 %, respectively, and minor embolic events 10.8% vs. 10.2%, respectively). Major hemorrhages occurred in 4.6% of patients in the higher intensity INR group compared to zero in the lower intensity INR group.

14.3 Myocardial Infarction

WARIS (The Warfarin Re-Infarction Study) was a double-blind, randomized study of 1214 patients 2 to 4 weeks post-myocardial infarction treated with warfarin (INR 2 to 4.8) or placebo. The primary endpoint was a composite of total mortality and recurrent infarction. A secondary analysis of cardiovascular events was assessed. Mean follow-up of the patients was 37 months. The results for each endpoint separately, including an analysis of vascular death, are provided in Table 7:

Table 7WARIS – Endpoint Analysis of Separate Events

Event	Warfarin (N=607)	Placebo (N=607)	RR (95% CI)	% Risk Reduction (p-value)
Total Patient Years of Follow-up	2018	1944		
Total Mortality	94 (4.7/100 py)	123 (6.3/100 py)	0.76 (0.60, 0.97)	24 (p=0.030)
Vascular Death	82 (4.1/100 py)	105 (5.4/100 py)	0.78 (0.60, 1.02)	22 (p=0.068)
Recurrent MI	82 (4.1/100 py)	124 (6.4/100 py)	0.66 (0.51, 0.85)	34 (p=0.001)
Cerebrovascular Event	20 (1/100 py)	44 (2.3/100 py)	0.46 (0.26, 0.79)	54 (p=0.002)

RR=Relative risk; Risk reduction=(1 - RR); CI=Confidence interval; MI=Myocardial infarction; py=patient years

WARIS II (The Warfarin, Aspirin, Re-Infarction Study) was an open-label, randomized study of 3630 patients hospitalized for acute myocardial infarction treated with warfarin to a target INR 2.8 to 4.2, aspirin 160 mg per day, or warfarin to a target INR 2 to 2.5 plus aspirin 75 mg per day prior to hospital discharge. The primary endpoint was a composite of all-cause mortality, recurrent myocardial infarction, stroke. The mean duration of observation was approximately 4 years. The results for WARIS II are provided in the Table 8.

Table 8WARIS II – Distribution of Events According to Treatment Group

Event	Aspirin (N=1816)	Warfarin (N=1256)	Aspirin plus Warfarin (N=1548)	Rate Ratio (95% CI)	p-value
	No. of Events				
Major Bleeding *	9	49	38	5.36 (NS)*	NS
				4.00 (NS)*	NS
Minor Bleeding #	39	103	133	3.20 (NS)*	NS
				2.48 (NS)*	NS
Composite Endpoints *	241	203	181	0.81 (0.69-0.95)*	0.009
				0.74 (0.62-0.89)*	0.001
Reinfarction	117	88	60	0.56 (0.43-0.76)*	0.0004
				0.74 (0.55-0.99)*	0.05
Thromboembolic Stroke	36	17	17	0.52 (0.28-0.98)*	0.05
				0.52 (0.28-0.97)*	0.03
Death	92	86	95		NS

Major bleeding episodes were defined as nonfatal cerebral hemorrhage or bleeding necessitating surgical intervention or blood transfusion.
The rate ratio for aspirin plus warfarin as compared with aspirin.*
The rate ratio is for warfarin as compared with aspirin.*
Minor bleeding episodes were defined as non-cerebral hemorrhage not necessitating surgical intervention or blood transfusion. #
Includes death, nonfatal reinfarction, and thromboembolic cerebral stroke.*
CI=confidence interval
NS=not determined

There were approximately four times as many major bleeding episodes in the two groups receiving warfarin than in the group receiving aspirin alone. Major bleeding episodes were not more frequent among patients receiving aspirin plus warfarin than among those receiving warfarin alone, but the incidence of minor bleeding episodes was higher in the combined therapy group.

15. REFERENCES

- Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonism. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed.. 2008;133:160S-198S. Chest
- Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physician Evidence-Based Clinical Practice Guidelines. 8th Ed.. 2008;133:454S-545S. Chest
- Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed.. 2008;133:546S-592S. chest
- Becker RC, Meade TW, Berger PB, et al. The primary and secondary prevention of coronary artery disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed.. 2008;133:776S-814S. Chest
- Salem DN, O'Gara PT, Madias C, Pauker SG. Valvular and structural heart disease. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed.. 2008;133:593S-629S.
- Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed.. 2008;133:887S-968S. Chest

16. HOW SUPPLIED/STORAGE AND HANDLING

NDC:64725-0856-1 in a BOTTLE of 100 TABLETS

17. PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Medication Guide).

Advise patients to:

- Tell their physician if they fall or bruise this may increase their risk for complications.
- Tell their physician if they are taking any medicines, including prescription and non-prescription drug, including salicylates (e.g., aspirin and topical analgesics), other over-the-counter drugs, and botanical (herbal) products except on advice of your physician.
- Notify their physician immediately if any unusual bleeding or symptoms occur. Signs and symptoms of bleeding include: pain, swelling or discomfort; prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
- Contact their doctor
  - immediately if they think they are pregnant
  - to discuss pregnancy planning
  - if they are considering breastfeeding
- Avoid any activity or sport that may result in traumatic injury.
- Obtain prothrombin time tests and make regular visits to their physician or clinic to monitor therapy.
- Carry identification stating that they are taking warfarin sodium.
- If the prescribed dose of warfarin sodium is missed, take the dose as soon as possible on the same day but do not take a double dose of warfarin sodium the next day to make up for missed doses.
- Eat a normal, balanced diet to maintain a consistent intake of vitamin K. Avoid drastic changes in dietary habits, such as eating large amounts of leafy, green vegetables.
- Contact their physician to report any serious illness, such as severe diarrhea, infection, or fever.
- If their therapy with warfarin sodium is discontinued, the anticoagulant effects of warfarin sodium may persist for about 2 to 5 days.

Manufactured by:
Cadila Healthcare Ltd.
Ahmedabad, India

Distributed by:

Zydus Pharmaceuticals USA Inc.

Pennington, NJ 08534

Rev. 06/12

Revision Date: 2012/06/25

MEDICATION GUIDE

, Warfarin Sodium Tablets USP

Read this Medication Guide before you start taking warfarin sodium and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about warfarin sodium when you start taking it and at regular checkups.

What is the most important information I should know about warfarin sodium?

Warfarin sodium can cause bleeding which can be serious and sometimes lead to death. This is because warfarin sodium is a blood thinner medicine that lowers the chance of blood clots forming in your body.

- You may have a higher risk of bleeding if you take warfarin sodium and:
  - are 65 years of age or older
  - have a history of stomach or intestinal bleeding
  - have high blood pressure (hypertension)
  - have a history of stroke, or "mini-stroke" (transient ischemic attack or TIA)
  - have serious heart disease
  - have a low blood count or cancer
  - have bad trauma, such as an accident or surgery
  - have kidney problems
  - take other medicines that increase your risk of bleeding, including:
    - a medicine that contains heparin
    - other medicines to prevent or treat blood clots
    - nonsteroidal anti-inflammatory drugs (NSAIDs)
  - take warfarin sodium for a long time. Warfarin sodium, USP is the active ingredient in warfarin sodium.

Tell your healthcare provider if you take any of these medicines. Ask your healthcare provider if you are not sure if your medicine is one listed above.

Many other medicines can interact with warfarin sodium and affect the dose you need or increase warfarin sodium side effects. Do not change or stop any of your medicines or start any new medicines before you tell to your healthcare provider.

Do not take other medicines that contain warfarin sodium while taking warfarin sodium.

- **Get your regular blood test to check for your response to warfarin sodium.**

This blood test is called an INR test. The INR test checks to see how fast your blood clots. Your healthcare provider will decide what INR numbers are best for you. Your dose of warfarin sodium will be adjusted to keep your INR in a target range for you.

- **Call your healthcare provider right away if you get any of the following signs or symptoms of bleeding problems:**
- pain, swelling, or discomfort
- unusual weakness, dizziness, or weakness
- unusual bruising (bruises that develop without known cause or grow in size)
- nosebleeds
- bleeding gums
- bleeding from cuts takes a long time to stop
- menstrual bleeding or vaginal bleeding that is heavier than normal
- pink or brown urine
- red or black stools
- coughing up blood
- vomiting blood or material that looks like coffee grounds
- Some foods and beverages can interact with warfarin sodium and affect your treatment and dose.
  - Eat a normal, balanced diet. Talk to your healthcare provider before you make any diet changes. Do not eat large amounts of leafy, green vegetables. Leafy, green vegetables contain vitamin K. Certain vegetable oils also contain large amounts of vitamin K. Too much vitamin K can lower the effect of warfarin sodium.
- Keep a list of all of your healthcare providers that you take warfarin sodium.
- Wear or carry information that you take warfarin sodium.

See **"What are the possible side effects of warfarin sodium?" for more information about side effects.**

What is warfarin sodium?

Warfarin sodium is prescription medicine used to treat blood clots and to lower the chance of blood clots forming in your body. Blood clots can cause a stroke, heart attack, or other serious conditions if they form in the legs or lungs.

It is not known if warfarin sodium is safe and effective in children.

Who should not take warfarin sodium?

Do not take warfarin sodium if:

- Your healthcare provider will decide if warfarin sodium is right for you. Talk to your healthcare provider about all of your health conditions. **your chance of having bleeding problems is higher than the possible benefit of treatment.**
- sodium may cause birth defects, miscarriage, or death of your unborn baby. **you are pregnant unless you have a mechanical heart valve. Warfarin**
- **allergic reaction to warfarin sodium or any other ingredients** in warfarin sodium. **See the end of this leaflet for a complete list of ingredients in warfarin sodium.**

What should I tell my healthcare provider before taking warfarin sodium?

Before you take warfarin sodium, tell your healthcare provider if you:

- have bleeding problems
- fall often
- have liver or kidney problems
- have high blood pressure
- have a heart problem called congestive heart failure
- have diabetes
- have had or may have surgery or a dental procedure
- have any other medical conditions
- are pregnant or plan to become pregnant. See " **Who should not take warfarin sodium?**"
- are breastfeeding. You and your healthcare provider should decide if you will take warfarin sodium and breastfeed.

Tell all of your healthcare providers and dentists that you are taking warfarin sodium. They should talk to the healthcare provider who prescribed warfarin sodium for you before you have surgery or dental procedure. Your warfarin sodium may need to be stopped for a short time or your may need your dose adjusted. **any**

, including prescription and non-prescription medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way warfarin sodium works. Certain medicines may increase your risk of bleeding. See " **Tell your healthcare provider about all the medicines you take What is the most important information I should know about warfarin sodium?**"

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine.

How should I take warfarin sodium?

- Your healthcare provider will adjust your dose from time to time depending on your response to warfarin sodium. **Take warfarin sodium exactly as prescribed.**
- **You must have regular blood tests and visits with your healthcare provider to monitor your response.**
- Take the dose as soon as possible on the same day. take a double dose of warfarin sodium the next day to make up for a missed dose. **If you miss a dose of warfarin sodium call your healthcare provider.Do not**
- Call your healthcare provider right away if you:
  - take too much warfarin sodium
  - are sick with diarrhea, an infection, or have a fever
  - fall or injure yourself, especially if you hit your head. Your healthcare provider may need to check you

What should I avoid while taking warfarin sodium?

- Do not do any activity or sport that may cause a serious injury.

What are the possible side effects of warfarin sodium?

Warfarin sodium may cause serious side effects including:

- See " **What is the most important information I should know about warfarin sodium?**"
- This can happen soon after starting warfarin sodium. It happens because blood clots form and block blood flow to an area of your body. Call your healthcare provider right away if you have pain, color, or temperature change in any area of your body. You may need medical care right away to prevent death or loss (amputation) of your affected body part. **Death of skin tissue (skin necrosis or gangrene).**
- Call your healthcare provider right away if you have pain in your toes and they look purple in color or dark in color. **"Purple toes syndrome."**

Tell your healthcare provider if you have any side effect that bothers you or does not go away.

These are not all of the side effects of warfarin sodium. For more information, ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store warfarin sodium?

- Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Protect from light.
- Dispense in a tight, light-resistant container as defined in the USP.

Keep warfarin sodium and all medicines out of the reach of children.

General information about warfarin sodium.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use warfarin sodium for a condition for which it was not prescribed. Do not give warfarin sodium to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about warfarin sodium. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about warfarin sodium that is written for healthcare professionals.

Please address medical inquiries to, (Medicalaffairs@zydususa.com) Tel.: 1-877-993-8779.

, What are the ingredients in warfarin sodium USP?

Active ingredient: Warfarin Sodium, USP

Inactive ingredients: hydroxypropyl cellulose, lactose monohydrate, magnesium stearate and pregelatinized starch. Additionally each 1 mg tablet contains D&C red no. 6 barium lake, 2 mg tablet contains FD&C blue no. 2 aluminum lake and FD&C red no. 40 aluminum lake, 2.5 mg tablet contains D&C yellow no. 10 aluminum lake and FD&C blue no. 1 aluminum lake, 3 mg tablet contains FD&C yellow no. 6 aluminum lake, FD&C blue no. 2 aluminum lake and FD&C red no. 40 aluminum lake, 4 mg tablet contains FD&C blue no. 1 aluminum lake, 5 mg tablet contains FD&C yellow no. 6 aluminum lake, 6 mg tablet contains FD&C yellow no. 6 aluminum lake and FD&C blue no. 1 aluminum lake, 10 mg tablet contains D&C yellow no. 10 aluminum lake and FD&C yellow no. 6 aluminum lake and 10 mg tablet is dye free

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Manufactured by:

Cadila Healthcare Ltd.

Ahmedabad, India

Distributed by:

Zydus Pharmaceuticals USA Inc.

Pennington, NJ 08534

Rev. 06/12

Revision Date: 2012/06/25

WARFARIN SODIUM TABLET

WARFARIN SODIUM

(warfarin sodium tablet)

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:64725-0058(NDC:69392-058)
Route of Administration	ORAL		

Active Ingredient/Active Moiety			
Ingredient Name		Basis of Strength	Strength
WARFARIN SODIUM (UNII: 4TOO7NBE4J) (WARFARIN - UNII:0QY7NY7S6X)		WARFARIN SODIUM	5 mg

Inactive Ingredients	
Ingredient Name	Strength
D&C YELLOW NO. 6 (UNII: H77VEI93A8)	
HYDROXYPROPYL CELLULOSE (TYPE H) (UNII: RFW2ET671P)	
LACTOSE MONOPHOSPHATE (UNII: T5O7T6P8EL)	
MAGNESIUM STEARATE (UNII: 70097M6I30)	
STARCH, CORN (UNII: O8232NY3SJ)	

Product Characteristics			
Color	ORANGE (PEACH)	Score	2 pieces
Shape	OVAL (ETTAL)	Size	5mm
Flavor		Imprint Code	WARF;
Contains			

Packaging				
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:64725-0058-1	100 in 1 BOTTLE		

Marketing Information			
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA090419	05/16/2008	

Labeler - TYA Pharmaceuticals (968389038)

Registrant - TYA Pharmaceuticals (968389038)

Establishment

Name	Address	ID/FEI	Business Operations
TYA Pharmaceuticals		968389038	MANUFACTURE(64725-0058) , REPACKAGE(64725-0058)